 PARIS CAMBRIDGE, Mass.--BUSINESS WIRE--NANOBIOTIX Paris:NANO NASDAQ:NBTX Euronext: NANO NASDAQ: NBTX the Company, a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, today announced positive first results from the complete phase Ib part of a phase IbII study evaluating NBTXR3 PEP503 activated by radiotherapy with concurrent chemotherapy. This study is sponsored and a 